Hematology Department, Venizelion Hospital of Heraklion, Heraklion, Greece.
Med Oncol. 2013 Mar;30(1):363. doi: 10.1007/s12032-012-0363-0. Epub 2012 Dec 25.
There are many growth factors influencing the expansion of multiple myeloma (MM). Angiogenesis is a process that may enhance MM growth, in various manners. Among them, insulin-like growth factor-1 (IGF-1) is a major factor, acting in many levels. The aim of the study was to measure serum levels of IGF-1 in newly diagnosed MM patients and to correlate them with clinical stage of the disease and with markers of angiogenesis, such as vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and interleukin-6 and 15 (IL-6 and IL-15). Serum levels of the above factors were measured, by ELISA, in 57 newly diagnosed MM patients and in 20 healthy controls. There was no difference in serum levels of IGF-1 in MM patients and in controls, contrary to angiogenic factors, which were higher in MM patients (p < 0.001). Similarly, IGF-1 did not correlate with clinical stage of the disease nor the other angiogenic factors, which also correlated with each other (p < 0.001). Serum IGF-1 concentrations are not influenced in MM patients. Therefore, although it is a proliferation cytokine, it cannot be used as marker of disease activity.
有许多生长因子影响多发性骨髓瘤（MM）的扩增。血管生成是一种可能以多种方式增强 MM 生长的过程。其中，胰岛素样生长因子-1（IGF-1）是一个主要因素，在多个层面发挥作用。本研究旨在测量新诊断 MM 患者的血清 IGF-1 水平，并将其与疾病的临床分期以及血管生成标志物（如血管内皮生长因子（VEGF）、肝细胞生长因子（HGF）、白细胞介素-6 和 15（IL-6 和 IL-15）相关联。通过 ELISA 测量了 57 名新诊断 MM 患者和 20 名健康对照者的上述因素的血清水平。与血管生成因子相比，MM 患者的血清 IGF-1 水平没有差异（p < 0.001），而血管生成因子在 MM 患者中更高。同样，IGF-1 与疾病的临床分期也没有相关性，其他血管生成因子也相互关联（p < 0.001）。MM 患者的血清 IGF-1 浓度不受影响。因此，尽管它是一种增殖细胞因子，但不能作为疾病活动的标志物。
